ADC Bio is developing new process technology to help drug developers meet conjugation process challenges in the testing and production of new antibody drug conjugate (ADC)-based anti cancer drugs. The technology signals faster, simpler and less costly development for an exciting new family of drugs.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.